AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05358457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Familiar Metacognitive Training
Description: The original metacognitive training program consist of 8 therapeutic units and 2 complementary. Seven of the therapeutic units address cognitive deviations and errors that are frequently seen in problem solving in schizophrenia, involved in the formation and maintenance of delusions. The other three units work with metacognition and the aims of the progra, as a psychoeducation session, so in total the MCTf will include 11 sessions.
Study NCT05733507 — intervention group
Intervention type: PROCEDURE
Intervention: IVT with tenecteplase or alteplase
Description: Patients received intravenous tenecteplase 0.25mg/kg (maximum dose: 25mg), administered as a bolus over 5 to 10 seconds or intravenous alteplase 0.9 mg/kg (maximum dose: 90mg), 10% as bolus and the remainder as continuous perfusion over 1 hour.
Study NCT05733507 — intervention group
Intervention type: PROCEDURE
Intervention: Intervention Name : Tirofiban and IVT with tenecteplase or alteplase
Description: IVT with tenecteplase or alteplase with continuous infusion of tirofiban 0.4µg/kg/min continued for 24 to 48 hours.
Study NCT05494294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraorally de-epithelialization
Description: In this group, the grafts were de-epithelialized at the donor site before harvesting. The calibrated surgeon removed the epithelium with a sharp Kirkland knife under magnification. To be sure of the elimination whole epithelial layer, bleeding was observed. Recipient site was prepared as follows; A after sulculer incision had done (blade 15c) two vertical incions were made from the gingival margin to 3 mm beyond the mucogingival junction A partial-thickness flap was elevated under the recession area and full thickness flap elevated adjacent flap portions. then relasing incisions were made apically from the mucogingival junction. After the preparation of the recipient site, obtained graft was sutured 1 mm apically to the cemento-enamel junction. Finally flap was positioned without tension and stabilized at least 2mm coronally from the cemento-enamel margin with the single interrupted sutures.
Study NCT05494294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extraorally de-epithelialization
Description: In this group, the grafts were de-epithelialized after graft harvesting. The calibrated surgeon removed the epithelium with 15 c knife under magnification. all remnants were removed under magnification. Same recipient site procedure was conducted in this group.
Study NCT05519670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib Oral Product
Description: Niraparib + capecitabine treatment
Study NCT05877807 — intervention group
Intervention type: DRUG
Intervention: Baclofen
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
Study NCT05877807 — intervention group
Intervention type: OTHER
Intervention: Placebo
Description: Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
Study NCT05466656 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous quality improvement cycle model
Description: The continuous quality improvement cycle model consist in a process of improvement by reference to a prior baseline clinical audit. It implies a local situation analysis, identifying barriers to improvements in clinical practice, and drawing up and implementing a plan of action for improving adherence to pre-established criteria. The goal is to establish interprofessional processes within the teams, in order to: examine the barriers that hinder the use of evidence in fostering best practices; and contribute to the development of implementation programmes for overcoming such obstacles.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture
Description: The acupuncture group will receive treatment with needles inserted at the specified acupoints. Selected by acupuncture experts, these acupoints include SP4 (Gongsun) , PC6 (Neiguan) , PC5 (Jianshi) and LV 3 (Taichong) bilaterally. All acupoints are localized according to the WHO Standard Acupuncture Locations.After needle insertion, the acupuncture needles will be manipulated using either the twirling-rotating or lifting-thrusting methods to achieve the De Qi sensation.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: escitalopram
Description: Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram
Description: Patients will receive 10 mg/day of escitalopram for the first 3 weeks and 20mg/day for the remaining 7 weeks.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham-acupuncure
Description: In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham-acupuncure
Description: In the sham acupuncture group, superficial skin penetration (2 to 3 mm in depth) at nonacupoints will be done without De Qi manipulations. Nonacupoints are away from conventional acupoints or meridians. The choice of sham acupuncture points, which are points located in an emplacement different than the meridian points. The sham acupoints are not standard acupoints and will be about 1cun ( ≈20 mm) lateral from the real acupoints in the experimental group.
Study NCT06451016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplements
Description: 70 mcg/day (equal to 2800 IU) of cholecalciferol
Study NCT06451016 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: escitalopram placebo
Description: Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
Study NCT05901571 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: escitalopram placebo
Description: Patients will receive 10 mg/day of escitalopram placebo for the first 3 weeks and 20mg/day for the remaining 7 weeks.
Study NCT05680935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood microRNA
Description: all patients will receive blood (20 ml) from the cubital vein for microRNA isolation.
Study NCT05680935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: plaque and intima microRNA
Description: The resulting surgical material will be sent for microRNA isolation.
Study NCT05680935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: histological examination of the plaque
Description: The resulting surgical material (atherosclerotic plaque) will be sent for histological examination.
Study NCT05680935 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood level trimethyl N-oxide
Description: all patients will receive blood (20 ml) from the cubital vein for determination of plasma trimethyl N-oxide (TMAO) content.
Study NCT06505876 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: including anti-infection therapy, blood pressure and blood glucose control
Study NCT06505876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: including anti-infection therapy, blood pressure and blood glucose control
Study NCT06505876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral Tube Feeding
Description: Before each feeding, inside and outside of the tube was cleaned with water. During feeding, the patient should maintain a semi-reclining or sitting position with mouth opened, and the tube was inserted slowly and smoothly into the upper part of the esophagus by medical staffs while the appropriate depth of intubation was checked with the calibration markings on the tube wall. The distance from the incisors to the head part of the tube should be between 22-25 cm. However, the specific depth should be evaluated based on patients' feedback and adjusted accordingly. After insertion, the tail part of the tube should be put into a container full of water and the absence of continuous bubbles indicated a successful intubation. Then, the feeding was to be conducted three times per day with 50 ml per minute and 400-600ml for each feeding.
Study NCT06505876 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasogastric Tube Feeding
Description: The feeding was conducted once every 3-4 hours, with 200-300ml each time. The total feeding volume was determined based on daily requirements. The feeding content was formulated by the nutritionists based on the patient\&#39;s condition and relevant guidelines to reach the energy demand as 20-25 kcal/kg/day and protein supplementation of 1.2-2.0 g/kg/day for both two groups. For patients with limited tube feeding compliance, we made appropriate adjustments to ensure that they were not at risk of severe malnutrition as much as possible.
Study NCT06064903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD7-CART01
Description: A single IV infusion of CD7-CART01 on Day 0
Study NCT05628519 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Captain Sonar Exposition
Description: Captain SonarTM is a naval battle game where two teams each composed of four participants clash. Each player has a well-defined role and it is imperative to communicate in a closed loop to advance in the game. This game also includes components similar to support for Trauma care: stress, speed of action, central communication and teamwork of four protagonists (Team Leader- Captain, intern-Second, nurse-Mechanic, Caregiver-Detector). This short video describes the rules and the Game progress: https://vimeo.com/173614346.
Study NCT05628519 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Monopoly Exposition
Description: Participant will be invited to play to Monopoly during 60 min
Study NCT04983771 — intervention group
Intervention type: DEVICE
Intervention: Annotate ultrasound scans
Description: Each expert will be asked to hand-labelled anatomical structures on relevant ultrasound images
Study NCT06231407 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Oriented CBTp Medication Management
Description: The prescriber structures the medication appointment to elicit and focus on subjects long term, valued goals (aspirations). With this information the prescriber will develop a plan to increase daily activity to facilitate the aspiration's pursuit. Obstacles (psychotic symptoms, motivational problems) will be identified and a formulation developed with the individual. Psychosocial interventions will be implemented for the various obstacles alongside monitoring and implementing of medications. Across sessions, the prescriber will continue to implement and monitor psychosocial interventions.
Study NCT06231407 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Residents will conduct medication management appointments as normally conducted
Study NCT05524636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise with peripheral magnetic stimulation of the abdominal wall muscles
Description: 8-week exercise program with peripheral magnetic stimulation, focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
Study NCT05524636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise of the abdominal wall muscles
Description: 8-week exercise program focused on abdominal wall muscles aiming to reduce subcutaneous fat, increase abdominal wall muscle strength and improve sitting postural control.
Study NCT06181695 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Administration of intranasal sufentanil
Study NCT04952636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopic Cuistow
Description: peforming the Cuistow Procedure under arthroscopy
Study NCT04952636 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: open Cuistow
Description: peforming the Cuistow Procedure with the traditional open process
Study NCT06181695 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Administration of intranasal sufentanil
Study NCT05160506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone is a steroid (corticosteroid) medication.
Study NCT05160506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50ml of 0.9% NACL will serve as the placebo
Study NCT05407805 — intervention group
Intervention type: OTHER
Intervention: Electronic Diary
Description: Participants will be asked to complete a daily electronic patient reported outcome diary entry to report on their experience in the past 24 hours.
Study NCT05733637 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention apply to study participants.
Study NCT06136351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 2 years of follow-up
Study NCT06515015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial Silicon Spigots
Description: The single-use endobronchial silicon spigot is injection-molded from implant-grade silicone and has a solid conical body. The endobronchial silicon spigot is used for the temporary occlusion of the target bronchus. It is delivered to the target bronchus through a bronchoscope using biopsy forceps, and the position of the blocker is adjusted to occlude the responsible bronchus leading to the pleural air leakage.
Study NCT06312163 — intervention group
Intervention type: DEVICE
Intervention: The contact lens to be investigated in this study (Scheimpflug topography derived corneal RGP contact lens design). A CE (UKCA) marked class 2 medical devices.
Description: The participants will be fitted with (i) the optimal lens design as specified by the virtual fitting module, in addition to (ii) lenses that are one clinically significant step (0.12 mm) flatter and (iii) steeper in axial edge lift (AEL).
Study NCT05502003 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Telerehabilitation-based high-intensity exercise training will be applied to the participants for 6 weeks, 3 times a week for 35 minutes, under the control of a physiotherapist.
Study NCT05502003 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Exercise Training
Description: The participants will be given telerehabilitation-based moderate exercise training under the control of a physiotherapist for 55 minutes, 3 times a week for 6 weeks.
Study NCT06032858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30mg twice daily
Study NCT05985707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN026
Description: KN026 is a novel bispecific antibody that simultaneously binds to two distinct HER2 epitopes.
Study NCT05985707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: KN046 is a novel bispecific antibody that blocks both PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86.
Study NCT05985707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: XELOX is the standard first-line chemotherapy in metastatic colorectal cancer and biliary duct cancer.
Study NCT04676893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D418 Tab.
Description: 1T
Study NCT04676893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-388 Tab.
Description: 1T
Study NCT04738175 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-AMG
Description: COVI-AMG is a fully human SARS-CoV-2 neutralizing monoclonal antibody (mAb)
Study NCT04738175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study NCT06136351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Study NCT06136351 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustin
Description: 90mg/m\^2 ivgtt, D0 of each 28-day cycle
Study NCT05959317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pilates Exercises
Description: Pilates exercises will be perform for 15-30 minutes for one session 3 days a week for 6-weeks than after 6 week reassess the QOL, pain and flexibility.
Study NCT05959317 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Neural dynamic mobilization
Description: Neural dynamic mobilization will be perform for 15-30 minutes for one session 3 days a week for 6-weeks after 6 weeks reassess the QOL, pain and flexibility.
Study NCT06281977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
Study NCT06281977 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Programed as dexmedetomidine on infusion pump.
Study NCT06379633 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In vivo exposure
Description: Exposure in vivo involves the confrontation with fear-evoking situations in real life.
Study NCT06379633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: (Virtual reality) exposure
Description: Exposure in virtual reality involves the confrontation with fear-evoking situations which are generated by a computer using VR technology.
Study NCT05946161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Health intervention to promote mental and sexual health of prostate cancer survivors
Description: An online psychological intervention (e-Health app technology) specifically tailored to meet the needs of Portuguese men with prostate cancer was developed to promote participants' mental and sexual health. The intervention protocol was designed under the principles of Cognitive Behavior Therapy (CBT), featuring psychological and sexual health promotion strategies. The intervention program consists of 5 modules covering components of psychoeducation, sexual rehabilitation, mindfulness, cognitive restructuring and relapse prevention. The modules will be delivered online (using text, videos, and graphics) along with therapeutic guidance and support provided by a certified Clinical Psychologist, over a 6-week period.
Study NCT04965298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole 30mg (as 2 x 15mg capsules) twice daily, 12 hours apart, for 12 months. IMP should be taken at least 30 minutes before food.
Study NCT04965298 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: Matched placebo 2 capsules twice daily, 12 hours apart, for 12 months. Treatment should be taken at least 30 minutes before food.
Study NCT04746664 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutritional counselling
Description: Individual-based nutrition counselling guided with the health belief model (HBM) and the theory of planned behavior (TPB) will be implemented.
Study NCT05045716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab IV infusion.
Study NCT05045716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lecanemab
Description: Lecanemab SC injection.
Study NCT04828707 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerivio active device
Description: Nerivio neurostimulator of conditional pain modulation (CPM)
Study NCT04828707 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nerivio sham device
Description: Nerivio neurostimulator with an electrical output not intended for neurostimulation
Study NCT06361966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d printed prosthetic socket
Description: 3d printed prosthetic socket produced through multi-jet fusion (MJF)
Study NCT06361966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3d printed prosthetic socket
Description: 3d printed prosthetic socket produced through multi-jet fusion (MJF)